

Kuen Chaang Uppertech Corp.

2024 Investor Conference

December 20. 2024



Safe Harbor Notice

- Forward-looking statements in this presentation, which may include statements about its results of operations, financial condition or business prospects, are subject to significant risks and uncertainties and are based on current expectations.
- Except as required by law, Kuen Chaang undertakes no obligation to update or revise any forward-looking statements with respect to the content of this presentation, whether as a result of new information, future events or otherwise.
- Any financial information contained here within is presented in conformity with International Financial Reporting Standards (IFRSs).
- You are urged to review carefully the information provided herein. This information shall not be distributed, reproduced or disclosed in whole or in part without prior written permission of Kuen Chaang Uppertech Corp.

Agenda

Group's Overview

Financial Results

Business Outlook

Q & A

Group's Overview History

1998年

- 成立堃昶股份有限公司，主要業務為電子零組件銷售，半導體之代理經銷。

2003年

- 獲主管機關通過核准上櫃。

2012年

- 取得仙桃牌商標及藥品許可證，百年漢方食品化，結合現代科技，積極擴展藥食同源之食品業務。

2017年

~2019年

- 因大陸市場的不確定性，堃昶公司轉為聚焦以信用良好的台商為主。

2022

~2023年

- 對100%轉投資子公司仁壽藥業有限公司增資至資本額新台幣2,000萬元整，並取得藥商資格。
- 經向衛福部中藥司申請，已核可「保血平丸」恢復生產製造及銷售。

2024年

- 100%轉投資子公司仁仙國際股份有限公司於民國113年2月17日停止實施多層次傳銷營業行為。
- 100轉投資子公司仁壽藥業有限公司於民國113年4月重新上市銷售「仙桃牌 保血平丸」，適應症為高血壓、腦溢血之中成藥。

Group's Overview **Major Client**



Financial Results

Concise Balance Sheet

		Unit : NT\$ Thousand	
Item	2023 Q3	2023	2024 Q3
Current assets	1,243,020	1,276,029	1,307,140
Non-current assets	269,929	261,339	249,422
Total Assets	1,512,949	1,537,368	1,556,562
Current liabilities	171,739	215,957	212,393
Non-current liabilities	14,765	8,378	3,956
Total Liabilities	186,504	224,335	216,349
Total Equity	1,326,445	1,313,033	1,340,213
Current ratio (%)	723.78	590.87	615.43
A/R turnover ratio (times)	3.12	3.25	3.78
A/R turnover days	116.99	112.31	96.56
Inventory turnover (times)	1.66	1.68	2.16

Financial Results


Concise Statement of Income

			Unit : NT\$ Thousand
Item	2023 Q1 - Q3	2023	2024 Q1- Q3
Operating revenue	518,703	704,031	426,289
COGS	595,990	755,917	405,655
Gross profit	(77,287)	(51,886)	20,634
Operating expenses	44,259	57,565	49,983
Operating income (lose)	(121,546)	(109,451)	(29,349)
Non-operating revenue and expenses	54,068	29,670	52,822
Profit (lose) before tax	(67,478)	(79,781)	23,473
Net profit (lose)	(58,956)	(68,682)	16,513
EPS	(0.50)	(0.58)	0.14

Financial Results

Consolidated revenue (by quarter)

	Unit : NT\$ Thousand	
Q / Y	2023	2024
Q1	211,487	195,824
Q2	127,433	121,281
Q3	179,783	109,184
Q4	185,328	
Total	704,031	426,289



2025 Business Outlook

- **KUEN CHAANG UPPERTECH CORP. :**

Continue to negotiate for new product line agents

- **Renshou Pharmaceutical Co., Ltd. :**

Develop new products and expand sales channels simultaneously

- **Note:**

For product information, please visit the Sentao official website.

- <https://www.sen-tao.com/pages/history>



